Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs. Analysts expect the Danish company to start catching up. Less ...
Novo Nordisk, to invest billions to increase manufacturing capacity. The company's stock closed more than 6% lower on Wednesday. Eli Lilly now expects full-year adjusted earnings of between ...
A new investigation found that such medicines can reduce the risk of Alzheimer's. While this new opportunity will take some time to cook before it's ready to delight shareholders, one of the two ...
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
As I write this, the stock has fallen by 12% just in ... As far as competition goes, Eli Lilly is one of the two ...
Today, Mounjaro and Zepbound both have become blockbusters, and in the most recent quarter, they generated $3.1 billion and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback